pegylated interferon a-2a

also known as pegIFN · PegINF

Developed for: chronic hepatitis B virus infection · chronic hepatitis C virus infection
Investigated by: Foundation for Liver Research

today NCT00877760 · Ph 4

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT00877760	Aug 2009 → Jul 2013	chronic hepatitis B virus infection	Foundation for Liver Research	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT00851890 Background	Mar → Jul 2009	chronic hepatitis C virus infection	AbbVie	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT01854528 Comparator	Jun 2013 → Nov 2014	chronic hepatitis C virus infection	AbbVie	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	pegylated interferon a-2a	“followed by 26 days of ABT-333 or placebo with pegylated interferon a-2a (pegIFN) and ribavirin (RBV) combination therapy.” NCT00851890 ↗ 2 NCT00877760 ↗ NCT01854528 ↗
Known as	pegIFN	“followed by 26 days of ABT-333 or placebo with pegylated interferon a-2a (pegIFN) and ribavirin (RBV) combination therapy.” NCT00851890 ↗
Known as	PegINF	“Pegylated Interferon a-2a (PegINF)” NCT01854528 ↗
Route	Subcutaneous	“Pegylated interferon was administered at 180 μg subcutaneously once a week” NCT00851890 ↗